Small-cap health care company Lexaria Bioscience has moved 16.6% this afternoon, reaching $0.86 per share. In contrast, the average analyst target price for the stock is $14.0.
Lexaria Bioscience Corp. operates as a biotechnology company. The company is based in Canada.
What to Consider if You Are Thinking of Buying Lexaria Bioscience:
Lexaria Bioscience has moved -65.6% over the last year.
LEXX has a forward P/E ratio of -1.0 based on its EPS guidance of -0.84.
Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of 7.7%.
Its Price to Book (P/B) ratio is 1.03
Lexaria Bioscience Has Negative Cash Flows
|Date Reported||Cash Flow from Operations ($ k)||Capital expenditures ($ k)||Free Cashflow ($ k)||YoY Growth (%)|
Averaging $-3.89 Million over the last 4 years, Lexaria Bioscience has consistently negative free cash flows. Their compounded average growth rate over this period is -7.3%, and their coefficient of variability is 24.5%.